Derivatives of 2-Aminopyridines as Inhibitors of Multidrug Resistant Staphylococcus Aureus Strains


  •  Iniobong Ante    
  •  Sherifat Aboaba    
  •  Hina Siddiqui    
  •  Muhammad Bashir    
  •  Muhammad Choudhary    

Abstract

A new series of 2-aminopyridine derivatives were synthesised. N-acylation of 2-amino-3-chloro-5-(trifluoromethyl) pyridine and 2-amino-5-(trifluoromethyl) pyridine with series of acid chlorides afforded a total of fourteen (14) amide compounds. The structures of the new compounds have been established by their IR, NMR and mass spectra data. All the compounds were tested for their activity against four (4) multi-drug resistant (MDR) bacteria Staphylococcus aureus strains using microplate alamar blue assay. The MDR-Staphylococcus aureus strains employed for this study were Epidermic Methicilin Resistant Staphylococcus aureus (EMRSA-17), Methicilin Resistant Staphylococcus aureus (MRSA-252), Epidermic Methicilin Resistant Staphylococcus aureus (EMRSA-16) and Pakistani Drug resistant clinical isolate of Staphylococcus aureus (PRSA). Other bacteria strains also used include Escherichia coli (ATCC 2592), Shigella flexenari (ATCC 12022), Staphylococcus aureus (NCTC 6571) and Pseudomonas aeruginosa (NCTC 10662). The synthesised compounds exhibited very good activity against the four MDR-Staphylococcus aureus strains of which most of the compounds showed higher potencies for inhibiting the growth of the strains than vancomycin, the standard drug employed. The compounds reported here may serve as the starting point for the design and development of MDR-S.aureus inhibitors as antibacterial agents.



This work is licensed under a Creative Commons Attribution 4.0 License.
  • Issn(Print): 1916-9698
  • Issn(Onlne): 1916-9701
  • Started: 2009
  • Frequency: quarterly

Journal Metrics

Google-based Impact Factor (2018): 10.07

h-index (August 2018): 23

i10-index (August 2018): 76

h5-index (August 2018): 9

h5-median(August 2018): 14

( The data was calculated based on Google Scholar Citations. Click Here to Learn More. )

Contact